- Business Wire•14 days agoFDA Approves Carnexiv™ (carbamazepine) injection as Intravenous Short-Term Replacement Therapy for Certain Seizure Types
Lundbeck announced today that the U.S. Food and Drug Administration has approved Carnexiv™ injection as a short-term replacement therapy for oral carbamazepine formulations in adults with certain seizure types when oral administration is temporarily not feasible.
- Business Wire•23 days agoPost-Hoc Analysis of Open-Label Extension Study Assesses the Use of ONFI® (Clobazam) CIV and the Potential for Tolerance
Results from a post-hoc analysis of an open-label extension study evaluating the potential of developing tolerance to adjunctive ONFI CIV in patients with Lennox-Gastaut syndrome were published online in Neurology.
- Bloomberg•28 days ago
H. Lundbeck A/S dropped the most in almost four years after its experimental Alzheimer’s drug failed to meet targets in a final-stage patient trial.
H. Lundbeck A/S (LUN.CO)
Copenhagen - Copenhagen Delayed Price. Currency in DKK
|Day's Range||222.90 - 227.00|
|52wk Range||193.20 - 290.50|
|1y Target Est||N/A|
|P/E Ratio (ttm)||-34.52|
|Avg Vol (3m)||326,182|
|Dividend & Yield||N/A (N/A)|